Related Experiment Video
Updated: May 23, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma
1Laura S. Wood.
Background:
Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), alone or in combination with immune checkpoint inhibitors, are part of the standard of care in treating metastatic renal cell carcinoma (mRCC). VEGFR-TKIs are associated with acute, chronic, and potentially dose-limiting toxicities requiring treatment modifications and discontinuations.
Objectives:
This article summarizes evidence-based practices that oncology nurses may use to manage VEGFR-TKI adverse events and improve quality of life in patients with mRCC.
Methods:
Pivotal clinical trial publications of VEGFR-TKIs in mRCC were reviewed to evaluate the adverse event profile of each drug and effective management strategies.
Findings:
Patients with mRCC treated with VEGFR-TKIs can benefit from education about potential side effects, consistent monitoring, and early detection of adverse events, as well as appropriate interventions to improve treatment tolerability, adherence, outcomes, and quality of life.
Insights
Oncology nurses can improve metastatic renal cell carcinoma (mRCC) treatment by managing vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) toxicities. Early detection and intervention enhance patient outcomes and quality of life.
Area of Science:
- Oncology
- Pharmacology
- Nursing
Background:
- Metastatic renal cell carcinoma (mRCC) treatment often involves vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs).
- VEGFR-TKIs, used alone or with immune checkpoint inhibitors, are standard care but cause significant toxicities.
- These toxicities necessitate treatment adjustments and can lead to discontinuation.
Purpose of the Study:
- To summarize evidence-based practices for oncology nurses managing VEGFR-TKI adverse events in mRCC patients.
- To provide strategies for improving patient quality of life during VEGFR-TKI therapy.
Main Methods:
- Review of pivotal clinical trial publications for VEGFR-TKIs in mRCC.
- Evaluation of adverse event profiles for each VEGFR-TKI drug.
- Identification of effective management strategies for identified adverse events.
Main Results:
- Patients with mRCC benefit from education on potential VEGFR-TKI side effects.
- Consistent monitoring and early detection of adverse events are crucial.
- Appropriate interventions improve treatment tolerability, adherence, and patient outcomes.
Conclusions:
- Proactive management of VEGFR-TKI adverse events is essential for mRCC patients.
- Oncology nurses play a vital role in optimizing VEGFR-TKI therapy through patient education and monitoring.
- Effective management strategies enhance treatment adherence, tolerability, and overall quality of life for patients with mRCC.
